Video

Dr. Yao on the Milan Criteria in Liver Cancer

Author(s):

Francis Yao, MD, professor of Clinical Medicine and Surgery, medical director of the Liver Transplant Program at UCSF Medical Center, discusses the Milan criteria in liver cancer.

Francis Yao, MD, professor of Clinical Medicine and Surgery, medical director of the Liver Transplant Program at UCSF Medical Center, discusses the Milan criteria in liver cancer.

In the past, oncologists tended to transplant bulky tumors and would often see their patients' disease recur, says Yao. The Milan criteria, which were published in 1996, state that a patient with hepatocellular carcinoma (HCC) is selected for transplantation when he or she has a single lesion up to 5 centimeters, or 2 to 3 lesions up to 3 centimeters.

After the Milan criteria became a benchmark for the treatment of patients with HCC, some oncologists began to question whether the size or number of lesions could be expanded. Research suggested that patients with tumor sizes just beyond the Milan criteria may see very positive outcomes, according to Yao. UCSF proposed an updated set of criteria, which expanded the upper limit of the tumor size by 1.5 centimeters, or up to 3 nodules with the largest lesion up to 4.5 centimeters.

<<<

View more from the 2016 International Liver Cancer Association Annual Conference

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Neil Iyengar, MD, and Chandler Park, MD, FACP
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Rena Callahan, MD, and Chandler Park, MD, FACP
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Virginia Kaklamani, MD, DSc, professor, medicine, Division of Hematology-Medical Oncology, The University of Texas (UT) Health Science Center San Antonio; leader, breast cancer program, Mays Cancer Center, UT Health San Antonio MD Anderson Cancer Center